By Matthias Blamont
PARIS (Reuters) – Pharmaceutical company Sanofi remains under pressure to launch new drugs and overcome setbacks in the COVID-19 vaccine race, despite a $3.2 billion deal to tighten its grip on promising mRNA technology.
On Tuesday,…
Analysis-Sanofi’s COVID-19 vaccine setback, drug pipeline cast long shadow
Share this article
More News
3 Crypto To Watch Amid The US-Israel Iran War
March 2, 2026
BCSC settles with director over alleged crypto fraud
March 2, 2026
